At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
AAV2-hCHMbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Safety Study in Subjects With CHM (Choroideremia) Gene Mutations Using an Adeno-Associated Virus Serotype 2 Vector to Deliver the Normal Human CHM Gene [AAV2-hCHM] to the Retina
In Brief
A Phase 2 clinical trial evaluating AAV2-hCHM for Choroideremia and CHM (Choroideremia) Gene Mutations. Completed, enrolled 15 participants across 3 sites.
Detailed Summary
This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroideremia, CHM (Choroideremia) Gene Mutations
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionOct 2022
TodayJul 2026
First PostedJan 19, 2015
Enrollment StartJan 15, 2015
Primary CompletionOct 12, 2022
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 11.5 years ago
Interventions
AAV2-hCHMbiological
Comparison of different dosages of AAV2-hCHM